Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT).

Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT). Hell J Nucl Med. 2016 Jun 22; Authors: Otte A Abstract Receptor-mediated radioimmunotherapy (RIT) has become an exciting field in nuclear medicine. In some indications we are succesful. Many concepts are experimental, although in use since many years, and only few, as e.g. (90)Y-ibritumomab tiuxetan, have gone to market but still pose a number of challenges. In this context, the review by Papamichail et al. in the Greek section of the Jan-Apr 2016 issue of the HJNM on receptor-mediated RIT regimens in neuroendocrine tumors including somatostatine analogues radiolabelled with (111)In, (90)Y, (177)Lu, and (213)Bi is most timely. The perception of RIT, as we think, still needs further attention and distribution as it is a valuable aid or even alternative to conventional therapy schemes. This could work if the partners, oncologists, nuclear medicine physicians, and health economists take up the discussion-together, not separately. And as peers. PMID: 27331218 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research